Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Vitamin D supplementation was more frequent among treated than untreated patients (79.3% vs. 29.8%, p < 0.001).

Source: Clinical Characteristics of the Patients. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Multiple reported designs.

Multiple reported designs

More than one design is explicitly reported; examine the supporting methods.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We performed a cross-sectional analysis of 1,103 patients aged ≥ 50 years hospitalized for fragility HF and evaluated within a Fracture Liaison Service.

Source: Abstract.

We performed a cross-sectional analysis of 1,103 patients aged ≥ 50 years hospitalized for fragility HF and evaluated within a Fracture Liaison Service.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Estimating the Extent of Missed Opportunities for Osteoporosis Treatment Before Hip Fracture Occurrence

Multiple reported designs · Calcified Tissue International · 2026

Original publication title

Estimating the Extent of Missed Opportunities for Osteoporosis Treatment Before Hip Fracture Occurrence

Gaetano Paride Arcidiacono; Marco Onofrio Torres; Chiara Ceolin; Mattia Giantin; Giovanni Tripepi; Valentina Camozzi; Anna Bertocco; Mor Peleg Falb; Martin Diogo; Francesca Guidolin; Giacomo Voltan; Maria Grazia Rodà; Elisa Pala; Andrea Angelini; Deris Gianni Boemo; Maria Vittoria Nesoti; Elena Campello; Pietro Ruggieri; Maria Fusaro; Paolo Simioni; Giuseppe Sergi; Sandro Giannini; Marina De Rui; Stefania Sella

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Hip fractures (HF) are among the most serious consequences of osteoporosis. Many individuals who subsequently sustain a HF may already fulfill recognized criteria for fracture risk assessment, bone mineral density (BMD) evaluation, or anti-osteoporosis treatment before the event occurs, yet remain unidentified and untreated. We aimed to quantify these missed opportunities for osteoporosis management prior to fragility HF occurrence. We performed a cross-sectional analysis of 1,103 patients aged ≥ 50 years hospitalized for fragility HF and evaluated within a Fracture Liaison Service.

Pre-fracture fracture risk was retrospectively estimated using FRAX® based on clinical risk factors only, excluding the index HF. Eligibility for anti-osteoporosis treatment and BMD assessment was evaluated according to international recommendations and national reimbursement criteria. Only 82 patients (7.4%) had received anti-osteoporosis therapy before the index HF. Female sex, rheumatologic diseases, chronic glucocorticoid therapy, and previous fractures were independently associated with prior treatment, whereas diabetes mellitus was negatively associated. Among patients aged 50 to 90 years, 69.6% would have been classified as being at high or very high fracture risk before fracture occurrence, yet only 10.2% had received anti-osteoporosis therapy.

Among the remaining patients, 90.3% already met indications for BMD assessment. Most patients who sustain a HF already meet recognized criteria for osteoporosis assessment or treatment but remain untreated. These findings highlight substantial missed opportunities for fracture prevention and support earlier identification and management of individuals at increased fracture risk.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00223-026-01594-8.

Authors’ abstract

Hip fractures (HF) are among the most serious consequences of osteoporosis. Many individuals who subsequently sustain a HF may already fulfill recognized criteria for fracture risk assessment, bone mineral density (BMD) evaluation, or anti-osteoporosis treatment before the event occurs, yet remain unidentified and untreated. We aimed to quantify these missed opportunities for osteoporosis management prior to fragility HF occurrence. We performed a cross-sectional analysis of 1,103 patients aged ≥ 50 years hospitalized for fragility HF and evaluated within a Fracture Liaison Service.

Pre-fracture fracture risk was retrospectively estimated using FRAX® based on clinical risk factors only, excluding the index HF. Eligibility for anti-osteoporosis treatment and BMD assessment was evaluated according to international recommendations and national reimbursement criteria. Only 82 patients (7.4%) had received anti-osteoporosis therapy before the index HF. Female sex, rheumatologic diseases, chronic glucocorticoid therapy, and previous fractures were independently associated with prior treatment, whereas diabetes mellitus was negatively associated. Among patients aged 50 to 90 years, 69.6% would have been classified as being at high or very high fracture risk before fracture occurrence, yet only 10.2% had received anti-osteoporosis therapy.

Among the remaining patients, 90.3% already met indications for BMD assessment. Most patients who sustain a HF already meet recognized criteria for osteoporosis assessment or treatment but remain untreated. These findings highlight substantial missed opportunities for fracture prevention and support earlier identification and management of individuals at increased fracture risk.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00223-026-01594-8.

Publication and source details

Original title: Estimating the Extent of Missed Opportunities for Osteoporosis Treatment Before Hip Fracture Occurrence

Gaetano Paride Arcidiacono; Marco Onofrio Torres; Chiara Ceolin; Mattia Giantin; Giovanni Tripepi; Valentina Camozzi; Anna Bertocco; Mor Peleg Falb; Martin Diogo; Francesca Guidolin; Giacomo Voltan; Maria Grazia Rodà; Elisa Pala; Andrea Angelini; Deris Gianni Boemo; Maria Vittoria Nesoti; Elena Campello; Pietro Ruggieri; Maria Fusaro; Paolo Simioni; Giuseppe Sergi; Sandro Giannini; Marina De Rui; Stefania Sella

Calcified Tissue International · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di Padova

Open access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:48:21.330879+00:00

DOI: 10.1007/s00223-026-01594-8 · PMC13525934